Name: Revestive

For Healthcare Professionals

Applies to teduglutide: subcutaneous kit


Uncommon (0.1% to 1%): Colorectal polyps
Rare (less than 0.1%): Malignancy[Ref]


Very common (10% or more): Fluid overload (up to 11.7%)
Common (1% to 10%): Flushing
Uncommon (0.1% to 1%): Syncope
Rare (less than 0.1%): Congestive heart failure
Postmarketing reports: Cardiac arrest, cardiac failure[Ref]


Very common (10% or more): Gastrointestinal stoma complication (up to 41.9%), abdominal pain (up to 37.7%), nausea (up to 27%), abdominal distension (up to 19.5%), vomiting (up to 14%)
Common (1% to 10%): Pancreatic disease, intestinal obstruction/stenosis, flatulence[Ref]

GI stoma complication (swelling of the stoma and associated complications) is considered a sign of efficacy rather than an adverse event.[Ref]


Common (1% to 10%): Gallbladder and biliary tract disease (cholecystitis, cholangitis, cholelithiasis, cholestasis), increased c-reactive protein[Ref]


Common (1% to 10%): Skin hemorrhage, allergic dermatitis[Ref]


Common (1% to 10%): Hypersensitivity reaction[Ref]


Very common (10% or more): Antibody formation (up to 48%)
Common (1% to 10%): Influenza

Nervous system

Very common (10% or more): Headache (up to 17%)
Common (1% to 10%): Paresthesia
Postmarketing reports: Cerebral hemorrhage[Ref]


Common (1% to 10%): Anxiety, sleep disturbance/disorder
Very rare (less than 0.01%): Mental status deterioration[Ref]


Very common (10% or more): Respiratory tract infection (up to 28%)
Common (1% to 10%): Dyspnea, cough[Ref]


Common (1% to 10%): Appetite disorder


Common (1% to 10%): Arthralgia


Very common (10% or more): Injection site reaction (up to 21.8%), peripheral edema (up to 10%)
Common (1% to 10%): Chest pain, night sweats


Common (1% to 10%): Renal colic, costovertebral angle tenderness

Some side effects of teduglutide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Usual Adult Dose for Short Bowel Syndrome

0.05 mg/kg administered by subcutaneous injection once a day.

Use: Treatment of patients with Short Bowel Syndrome who are dependent on parenteral support.